Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
GENERIC NAME: becaplermin
BRAND NAME: Regranex
DRUG CLASS AND MECHANISM: Becaplermin is a gel applied topically to diabetic ulcers on the lower limbs (foot, ankle, and leg) to promote healing of the ulcers. It belongs to a class of drugs called platelet-derived growth factors or PDGFs. Designed to mimic naturally-occurring PDGF, becaplermin is man-made using recombinant DNA technology. Becaplermin, or as it also is known, recombinant human PDGF (rhPDGF-BB), is active early in the process of ulcer healing. Wound and ulcer healing is a three-phased process that the body initiates after an injury to the skin. The process begins with the first phase, inflammation. In this phase, blood flow and fluid increase around the site of the ulcer. If there is bleeding from injured blood vessels, platelets from the blood invade the site of the ulcer and cause the blood to clot. This stops the bleeding. Platelets also release chemical messengers (proteins) called platelet- derived growth factors (PDGFs). These PDGFs send signals to cells around the ulcer and recruit them to the site of the ulcer where they initiate the second phase of the healing process, called proliferation. In this phase tissue is repaired and, if the injury is deep enough, scar tissue forms.The remaining cells of the normal skin divide and produce new cells to replaced the damaged cells.
Diabetic ulcers heal slowly and sometimes not at all because the healing process is impaired, probably because blood flow to the skin is reduced in people with diabetes. This can lead to serious bacterial infections within the ulcers which can spread and necessitate amputation of the foot or leg. Becaplermin acts along with naturally- occurring PDGF to expedite the recruitment of cells to the ulcer, promote the division of cells and the formation of new skin. Remodeling, the third and final phase of wound healing, restructures the healed ulcer, and the scar tissue that has formed is broken down. As a result of remodeling, the new skin assumes the appearance of the old skin. Becaplermin is the first drug that can be applied directly to the ulcer that is designed to promote healing. It was approved by the FDA on December 16 1997.
Medically Reviewed by a Doctor on 3/21/2013
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index